


**CLIENT PHOTOGRAPH**



**PATIENT NAME : NARSIMLOO KURMA**

**REF : MEDIWHEEL**

**AGE : 57 YEARS**

**SEX : MALE**



**CLIENT SIGN**

  
**SIGNATURE**

**A Unit of Avanathi Health Care PVT. LTD.**

# 266, Main Road, Vivekananda Nagar, Kukatpally, Hyderabad-500 072., P: 040-23 16 11 20, M: +91 8008804014

# S.R. Nagar Circle, Near Umesh Chandra Statue, Hyderabad-500 038., P: 040-29 56 56 56, M: +91 8008804014

# 2-48/98/a/nr, Telecom Nagar, Main Road, Opp to Cultfit, Beside Medplus, Gachibowli - 500032., M: +91 9515978234





**భారత ప్రభుత్వము**  
**Government of India**

**భారత విశిష్ట గుర్తింపు ప్రాధికార సంస్థ**  
**Unique Identification Authority of India**

నమోదు సంఖ్య / Enrollment No. : 2081/12085/32032

To  
**Kurma Narsimuloo**  
కుర్మా నర్సిములూ  
S/O: K Gandepa,  
2-1-40/10E,  
bhavani nagar,  
sai pur,  
VTC: Tandur, PO: Tandur,  
Sub District: Tandur, District: K.v. Rangareddy,  
State: Telangana, PIN Code: 501141,  
Mobile: 9642133188

81748349



*Narsimuloo*

మీ ఆధార్ సంఖ్య / Your Aadhaar No. :

**9758 1016 4727**


**నా ఆధార్, నా గుర్తింపు**



**భారత ప్రభుత్వము**  
**Government of India**



Issue Date: 31/12/2012



కుర్మా నర్సిములూ  
**Kurma Narsimuloo**  
పుట్టిన తేదీ / DOB: 06/04/1965  
పురుషుడు / Male

**9758 1016 4727**



Name : **NARSIMLOO KURMA**  
 Age/Gender : 57YEARS/MALE  
 Sample Type : WB EDTA  
 Ref By : MEDIWHEEL

Patient Id : 5603  
 Sample Drawn Date : 29-Aug-2022  
 Reported Date : 30-Aug-2022

**HEMATOLOGY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>COMPLETE BLOOD COUNT</b>			
Hemoglobin	15.1	gm/dL	Male : 13.0 - 18.0 Female : 11.5 - 16.0
Erythrocyte Count (RBC Count)	5.1	mill/uL	Male : 4.5 - 5.5 Female : 3.8 - 4.8
Hematocrit (HCT)	46.2	%	Male : 40 - 54 Female : 35 - 47
Platelet (Method : Cell Counter )	2.0	lakhs/cumm	1.50 - 4.50
<b>Red Cell Indices</b>			
MCV	91	fl	83 - 101
MCH	29	pg	27 - 32
MCHC (Method : Cell Counter )	32	pg	31.5 - 34.5
<b>Total Count and Differential Count</b>			
Total WBC Count	6580	cells/cumm	4000 - 11000
Nuetrophils	45	%	40 - 75
Lymphocytes	40	%	20 - 40
Eosinophils	08	%	0 - 6
Monocytes	07	%	2 - 10
Basophils (Method : Cell Counter )	00	%	0 - 1
<b>MICROSCOPIC BLOOD PICTURE</b>			
RBC Morphology	NORMOCYTIC/NORMOCHROMIC		
WBC Morphology	EOSINOPHILIA		
Platelete Morphology	ADEQUATE		
<b>Method:</b> Cell Counter			

-----End of the Report-----

**DR. S. V. RAMANA MD.,  
Chief Pathologist**

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
 Note : This Report is subject to the terms and conditions mentioned overleaf  
 Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED






Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : SERUM,Urine  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>FBS &amp; PLBS</b>			
Fasting Blood Sugar	88	mg/dl	60 - 110
Fasting Urine Glucose (Method :Strip )	NIL		
Post Prandial Blood Sugar - PLBS	120	mg/dL	110 - 160
Post Prandial Urine Glucose (Method :Strip )	NIL		

-----End of the Report-----



**DR. S. V. RAMANA MD.**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Wealthy Living





Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : WB EDTA  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>GHB/HbA1c</b>			
GLYCOSYLATED HAEMOGLOBIN (HbA1c)	5.6		< 6.0 : Non Diabetic 6.0 - 7.0 : Good Control 7.0 - 8.0 : Poor Control > 8 : Alert

-----End of the Report-----



**DR. S. V. RAMANA MD.**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Wealthy Living



Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : SERUM  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>KID-PRO</b>			
SERUM CREATININE	0.8	mg/dL	0.7 - 1.2
BLOOD UREA	23.8	mg/dL	17 - 43
SERUM URIC ACID	8.5	mg/dL	3.5 - 7.2
SERUM CALCIUM	9.7	mg/dL	8.4 - 10.5

-----End of the Report-----



**DR. S. V. RAMANA MD.**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Wealthy Living






Name : **NARSIMLOO KURMA**  
 Age/Gender : 57YEARS/MALE  
 Sample Type : SERUM  
 Ref By : MEDIWHEEL

Patient Id : 5603  
 Sample Drawn Date : 29-Aug-2022  
 Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>LIPID PROFILE</b>			
Total Cholesterol (Method :CHOD/PAP )	171	mg/dL	<200:Desirable 200 - 239 : Borderline risk >240:High Risk
Cholesterol - HDL (Method :Direct )	42	mg/dL	< 40 : Low 40 - 60 : Optimal  > 60 : Desirable 0 - 5.0
Total cholesterol/HDL ratio (Method :Calculated )	4.1		0 - 5.0
Cholesterol - LDL (Method :Calculated )	101	mg/dL	< 100 : Normal 100 - 129 : Desirable  130 - 159 : Borderline-High 160 - 189 : High > 190 : Very High
Cholesterol VLDL (Method :Calculated )	28.4	mg/dL	7-40
Triglycerides (Method :Lipase/Glycerol Kinase )	142	mg/dL	< 150 :Normal 150-199 :Borderline-High  200-499 :High > 500 :Very High



-----End of the Report-----

**DR. S. V. RAMANA MD.**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
 Note : This Report is subject to the terms and conditions mentioned overleaf  
 Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Wealthy Living



Name : **NARSIMLOO KURMA**  
 Age/Gender : 57YEARS/MALE  
 Sample Type : SERUM  
 Ref By : MEDIWHEEL

Patient Id : 5603  
 Sample Drawn Date : 29-Aug-2022  
 Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>LIVER FUNCTION TEST (LFT)</b>			
BILIRUBIN - TOTAL	0.7	mg/dL	Upto 1.0
BILIRUBIN - DIRECT	0.1	mg/dL	0.0 - 0.2
BILIRUBIN - INDIRECT	0.6	mg/dL	0.0 - 0.8
S.G.O.T	14	U/L	UP TO 35
S.G.P.T	25	IU/L	UP TO 40
ALKALINE PHOSPHATASE	45	U/L	Adults : 15 - 112 Children : 45 - 325
TOTAL PROTEINS	7.3	Gms/dL	6.0 - 8.0
ALBUMIN	4.3	Gms/dL	3.5 - 5.0
GLOBULIN	3.0	Gms/dL	1.5- 3.5
A / G Ratio	1.4		

-----End of the Report-----

**DR. S. V. RAMANA MD.**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
 Note : This Report is subject to the terms and conditions mentioned overleaf  
 Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Healthy Living





Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : --  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
Prostate Specific Antigen (Total) (Method :CLIA )	0.17		<=40 years :<1.4 ng/ml 41-50 years :<2.0 ng/ml 51-60 years :<3.1 ng/ml 61-70 years :<4.1 ng/ml >= 70 years<4.4 ng/ml

-----End of the Report-----



**DR. S. V. RAMANA MD.**  
**Chief Pathologist**

**Interpretation:**

Measurement of serum PSA levels is not recommended as a screening procedure for the diagnosis of cancer because elevated PSA levels also are observed in patients with benign prostatic hypertrophy. However, studies suggest that the measurement of PSA in conjunction with digital rectal examination (DRE) and ultrasound provide a better method of detecting prostate cancer than DRE alone.  
PSA levels increase in men with cancer of the prostate, and after radical prostatectomy PSA levels routinely fall to the undetectable range. If prostatic tissue remains after surgery or metastasis has occurred, PSA appears to be useful in detecting residual and early recurrence of tumor. Therefore, serial PSA levels can help determine the success of prostatectomy, and the need for further treatment, such as radiation, endocrine or chemotherapy, and in the monitoring of the effectiveness of therapy.

Healthy testing for Wealthy living



Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : SERUM  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**CLINICAL BIOCHEMISTRY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>Thyroid Profile</b>			
TOTAL TRIIODOTHYRONINE (T3)	125.10	ng/dL	87 - 178
TOTAL THYROXINE (T4)	9.65	ug/dL	6.09 - 12.23
THYROID STIMULATING HORMONE (TSH)	3.68	μIU/mL	0.38 - 5.33

-----End of the Report-----



**DR. S. V. RAMANA MD.**  
**Chief Pathologist**

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED





Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : WB EDTA  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**HEMATOLOGY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
------------------	--------	-------	-----------------

**Blood Grouping (A B O) and Rh typing\***

Blood Grouping (ABO)	"B"		
Rh Typing	Positive		
<b>Method:</b> Tube method			

-----End of the Report-----



**DR. S. V. RAMANA MD.,**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED



Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : WB EDTA  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**HEMATOLOGY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>ERYTHROCYTE SEDIMENTATION RATE(ESR)</b>			
FIRST HOUR	22	mm	1 - 10
-----End of the Report-----			



**DR. S. V. RAMANA MD.,**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Wealthy Living





Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Sample Type : Urine  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 30-Aug-2022

**CLINICAL PATHOLOGY**

TEST DESCRIPTION	RESULT	UNITS	REFERENCE RANGE
<b>CUE- (OP)</b>			
<b>PHYSICAL EXAMINATION</b>			
Quantity	20 ml		
Colour	PALE YELLOW		
Clarity	CLEAR		
Reaction (pH)*	Acidic		
Specific gravity	1.015		
<b>CHEMICAL EXAMINATION</b>			
Albumin	Nil		
Sugar	Nil		
Bile salts	Absent		
Bile pigments	Absent		
<b>MICROSCOPIC EXAMINATION</b>			
PUS CELLS	2-3	/ HPF	
Epithelial Cells	2-3	/ HPF	
R.B.Cs	Nil		
CASTS	Nil		
CRYSTALS	Nil		
OTHERS	Absent		

Method: Strip/Microscopy

-----End of the Report-----

**DR. S. V. RAMANA MD.**  
Chief Pathologist

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note: This Report is subject to the terms and conditions mentioned overleaf  
Note: PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

Healthy testing for Wealthy living



PATIENT ID : 5603  
PATIENT NAME : NARASIMLOO KURMA 57/M

Summary Report  
August 29, 2022

Report time : 01:50 pm  
August 29, 2022 01:50 pm

PROTOCOL : BRUCE  
PATIENT HEIGHT : 168 Cm  
PATIENT WEIGHT : 0.00 Kg  
PATIENT ADD :

Ref. By : Not Applicable  
( Not Applicable )

Stage	Stage Time	Speed (Kmph) / Grade (%)	HR bpm	BP mmHg	R.P.P. X 1000	METS	ST Level I	Stage Comments
Pre-Test	00:51	0.00 / 0.00	73	120 / 80	8	1.00	1.13	
Supine	00:31	0.00 / 0.00	72	120 / 80	8	1.00	0.68	
Standing	00:31	0.00 / 0.00	71	120 / 80	8	1.00	0.71	
Hyper-Ventilation	00:27	0.00 / 0.00	68	120 / 80	8	1.00	0.71	
Wait For Exercise	00:23	0.00 / 0.00	77	120 / 80	9	1.00	0.58	
Exercise Stage 1	03:00	2.70 / 10.00	105	130 / 80	13	5.70	0.64	
Exercise Stage 2	03:00	4.00 / 12.00	114	140 / 90	15	8.00	0.81	
Exercise Stage 3	03:00	5.50 / 14.00	128	150 / 90	19	10.60	0.42	
Peak Exercise	01:36	6.80 / 16.00	142	150 / 90	21	13.00	0.58	
Recovery 1	01:00	0.00 / 0.00	103	150 / 90	15	1.00	0.77	
Recovery 3	03:00	0.00 / 0.00	91	130 / 80	11	1.00	0.84	
Recovery 6	06:00	0.00 / 0.00	86	120 / 80	10	1.00	0.52	

TOTAL EXER TIME : 10 : 36 min  
MAX WORKLOAD : 13.00

MAX HR : 142 bpm (87.12 % of 163 bpm)  
DISTANCE COVERED : 0.79 Km

MAX BP : 150 / 90 mmHg  
DOUBLE PRODUCT : 21300.00

**N. SREEKANTH**  
DR  
Associate Cardiologist  
No. 569886  
MP, FCC



PATIENT ID : 5603  
PATIENT NAME : NARASIMLOO KURMA 57/M

Summary Report

August 29, 2022

Report time :  
August 29, 2022

01:50 pm

PROTOCOL : BRUCE  
PATIENT HEIGHT : 168 Cm  
PATIENT WEIGHT : 0.00 Kg  
PATIENT ADD :

Ref. By : Not Applicable  
( Not Applicable )

OBJECT OF TEST  
RISK FACTOR  
ACTIVITY  
MEDICATION  
BRIEF HISTORY  
OTHER INVESTIGATION  
REASON FOR TERMINATION  
EXERCISE TOLERANCE  
EXERCISE INDUCED ARRHYTHMIA  
HAEMO RESPONSE  
CHRONO RESPONSE  
FINAL IMPRESSION

Nil

Nil is low probability for inducible ischemia.

**DR. N. SREEKANTH**  
MD, FGC  
Associate Cardiologist  
No. 56986  
DR  
CARDIOLOGIST




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57M  
PROTOCOL : BRUCE  
STAGE : Pre-Test  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 01:51 pm  
PHASE TIME : 00:51  
STAGE DURATION : 00:00  
HR : 73 bpm  
SPEED: 0.0 kmph  
GRADE: 0.0  
BP : 120 / 80 mmHg  
METs : 1.00



100 Hz

10mm/mv, 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57M  
PROTOCOL : BRUCE  
STAGE : Supine  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 01:51 pm  
PHASE TIME : 01:23  
STAGE DURATION : 00:00  
HR : 72 bpm  
SPEED: 0.0 kmph  
GRADE: 0.0  
BP : 120 / 80 mmHg  
QRS Lead : V5  
METs : 1.00






APPLE DIAGNOSTICS

Linked Median Report

August 29, 2022 01:50 pm  
Report time : 01:52 pm

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M  
PROTOCOL : BRUCE  
STAGE : Standing  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

PHASE TIME : 01:54  
STAGE DURATION : 00:00  
HR : 71 bpm  
QRS Lead : V5  
SPEED: 0.0 kmph  
GRADE: 0.0  
BP : 120 / 80 mmHg  
METs : 1.00



100 Hz

10mm/mv, 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M  
PROTOCOL : BRUCE  
STAGE : HyperVentilation  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 01:52 pm  
PHASE TIME : 02:22 SPEED: 0.0 kmph  
STAGE DURATION : 00:00 GRADE: 0.0  
HR : 68 bpm BP : 120 / 80 mmHg  
QRS Lead : V5 METs : 1.00



100 Hz

10mm/mv, 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M  
PROTOCOL : BRUCE  
STAGE : Wait For Exercise  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 01:53 pm  
PHASE TIME : 02:45  
STAGE DURATION : 00:00  
HR : 77 bpm  
SPEED: 0.0 kmph  
GRADE: 0.0  
BP : 120 / 80 mmHg  
QRS Lead : V5  
METs : 3.40





APPLE DIAGNOSTICS


Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M

PROTOCOL : BRUCE  
STAGE : Exercise Stage 1  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 01:56 pm

PHASE TIME : 03:00 SPEED: 2.7 kmph  
STAGE DURATION : 03:00 GRADE: 10.0  
HR : 105 bpm BP : 130 / 80 mmHg  
QRS Lead : V5 METs : 5.70



100 Hz

10mm/mv 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M  
PROTOCOL : BRUCE  
STAGE : Exercise Stage 2  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 01:59 pm  
PHASE TIME : 06:00  
STAGE DURATION : 03:00  
HR : 114 bpm  
SPEED: 4.0 kmph  
GRADE: 12.0  
BP : 140 / 90 mmHg  
QRS Lead : V5  
METs : 8.00



100 Hz

10mm/mv, 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M

PROTOCOL : BRUCE  
STAGE : Exercise Stage 3  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 02:02 pm  
PHASE TIME : 09:00 SPEED: 5.5 kmph  
STAGE DURATION : 03:00 GRADE: 14.0  
HR : 128 bpm BP : 150 / 90 mmHg  
QRS Lead : V5 METS : 10.60



100 HZ

10mm/mv, 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M

PROTOCOL : BRUCE  
STAGE : Peak Exercise  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 02:03 pm  
PHASE TIME : 10:37  
STAGE DURATION : 01:37  
HR : 142 bpm  
SPEED: 6.8 kmph  
GRADE: 16.0  
BP : 150 / 90 mmHg  
METS : 13.00



100 Hz

10mm/mv, 25mm/sec




APPLE DIAGNOSTICS

Linked Median Report

PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg  
PATIENT NAME : NARASIMLOO KURMA 57/M  
PROTOCOL : BRUCE  
STAGE : Recovery  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

August 29, 2022 01:50 pm  
Report time : 02:04 pm  
PHASE TIME : 10:37 SPEED: 0.0 kmph  
STAGE DURATION : 01:00 GRADE: 0.0  
HR : 103 bpm BP : 150 / 90 mmHg  
GRS Lead : V5 METS : 1.00






PROTOCOL : BRUCE  
STAGE : Recovery  
ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

Linked Median Report  
August 29, 2022 01:50 pm

Report time : 02:06 pm  
PHASE TIME : 10:37  
STAGE DURATION : 03:00  
HR : 91 bpm  
SPEED: 0.0 kmph  
GRADE: 0.0  
BP : 130 / 80 mmHg  
METS : 1.00



100 Hz

10mm/mv, 25mm/sec



PATIENT ID : 5603 HEIGHT : 168 Cm WEIGHT : 0.00 Kg

PATIENT NAME : NARASIMLOO KURMA 57/M

PROTOCOL : BRUCE

STAGE : Recovery

ST Levels (mm) / ST Slope (mV/s) measured at 80 ms Post J

Linked Median Report

August 29, 2022

01:50 pm

August 29, 2022

01:50 pm

Report time

02:09 pm

PHASE TIME

: 10:37

STAGE DURATION

: 06:00

HR

: 86 bpm

GRS Lead


V5

SPEED: 0.0 kmph

GRADE: 0.0

BP : 120 / 80 mmHg

METs : 1.00




100 Hz

10mm/mV 25mm/sec













<b>Patient ID:</b> 5603MED	<b>Patient Name:</b> NARSIMLOO KURMA.57YM
<b>Age:</b>	<b>Sex:</b>
<b>Accession Number:</b> ACCNO008279	<b>Modality:</b> CR
<b>Referring Physician:</b> MEDIWHEEL	<b>Study:</b> CHEST
<b>Study Date:</b> 29-Aug-2022	

**X - RAY CHEST PA VIEW**

Trachea is in midline.  
Both hila normal in density.  
Cardiac silhouette maintained.  
Both CP angles are clear.  
Both lung parenchyma are normal.  
Bony cage and soft tissues are normal.



**IMPRESSION: NORMAL STUDY.**

**For clinical correlation.**

**Dr. Sukumar.,MDRD**  
Consultant Radiologist

Date: 29-Aug-2022 10:14:02





**APPLE DIAGNOSTIC**

— MEDICAL CENTRE —

AN ISO CERTIFIED



Name : **NARSIMLOO KURMA**  
Age/Gender : 57YEARS/MALE  
Reff By : MEDIWHEEL

Patient Id : 5603  
Sample Drawn Date : 29-Aug-2022  
Reported Date : 29-Aug-2022

**RADIOLOGY**

**DEPARTMENT OF RADIOLOGY  
ULTRASOUND SCAN OF WHOLE ABDOMEN**

**LIVER** : Normal in size 115 mm with normal echotexture. No focal lesions or dilated biliary radicles. No IHBD / CBD dilatation. Portal vein is normal.

**GALL BLADDER** : Partially Distended

**SPLEEN** : Normal in size 89 mm with normal echotexture. No focal lesions.

**PANCREAS** : Head, body, visualized parts of tail are normal. No focal lesions or peripancreatic collections are seen

**RIGHT KIDNEY** : Measuring 87 x 40 mm, E/o few calculi noted measuring 7 mm at largest pole

**LEFT KIDNEY** : Measuring 83 x 45 mm, E/o few calculi noted measuring 20mm at largest pole

**URINARY BLADDER** : Distended

**PROSTATE** : Normal in size ( Vol : 15 cc ), contour and echotexture.


No ascites or lymphadenopathy is seen.

**IMPRESSION :**

\* **SIMPLE RIGHT RENAL CORTICAL CYST**

\* **NON OBSTRUCTIVE BILATERAL CALCULI.**

**FOR CLINICAL CORRELATION AND FURTHER EVALUATION IF INDICATED.**



**Radiologist**

Assay result should be correlated clinically with other laboratory finding and the total clinical status of the patient.  
Note : This Report is subject to the terms and conditions mentioned overleaf  
Note : PARTIAL REPRODUCTION OF THIS REPORT IS NOT PERMITTED

**A Unit of Avanthi Health Care PVT. LTD.**

Note: This Report is subject to the terms and conditions mentioned overleaf

web: [www.applediagnostic.com](http://www.applediagnostic.com)  
e-mail: [applediagnostichyd@gmail.com](mailto:applediagnostichyd@gmail.com)

Healthy testing for Wealthy Living



Narsimloo Kungu

